• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Gabapentin effective for chronic cough

News
Article

Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet.

Gabapentin may be an effective and well-tolerated treatment for patients with refractory chronic cough, according to a study published August 28 in The Lancet.

Over a 2-year period, Nicole M. Ryan, PhD, of The University of Newcastle and John Hunter Hospital in NSW, Australia, and colleagues recruited 62 adult patients with refractory chronic cough lasting longer than 8 weeks from the John Hunter Hospital respiratory outpatient clinic. Patients were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1,800 mg) or matching placebo for 10 weeks.

The researchers noted that gabapentin significantly improved cough-specific quality of life compared with placebo. Ten patients (31%) experienced side effects, the most common being nausea and fatigue compared with 3 patients (10%) in the placebo group.

These positive effects suggest that central reflex sensitization is a relevant mechanism in refractory chronic cough, and that gabapentin might be an effective therapy, the authors wrote.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.